- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Effects of Ixeris dentata water extract and caffeic acid on allergic inflammation in vivo and in vitro
© Jeon et al. 2015
Received: 21 October 2014
Accepted: 29 May 2015
Published: 24 June 2015
Ixeris dentata Nakai has been used for the treatment of mithridatism, calculous, indigestion, pneumonia, hepatitis, and tumors in Korea, China, and Japan. However, the effect of a water extract of Ixeris dentata (ID) and its molecular mechanism on allergic inflammation has not been elucidated. In this study, we attempted to evaluate the effects of ID and its major compound caffeic acid on allergic inflammation in vivo and in vitro.
ID was applied to 2, 4-dinitrofluorobenzene (DNFB)-induced atopic dermatitis (AD)-like skin lesion mice and immune cell infiltration, cytokine production, and the activation of mitogen-activated protein kinases (MAPKs) were investigated. Moreover, the effect of ID on compound 48/80-induced anaphylactic shock was investigated in a mouse model. The human keratinocyte cell line (HaCaT cells) and human mast cells (HMC-1) were treated with ID or caffeic acid to investigate the effects on the production of chemokines and proinflammatory cytokines and on the activation of MAPKs.
ID inhibited the serum levels of IgE and interleukin (IL)-1β in DNFB-induced AD-like skin lesion mouse models and suppressed anaphylactic shock in the mouse models. ID and caffeic acid inhibited the production of chemokines and adhesion molecules in HaCaT cells. In addition, ID reduced the release of tumor necrosis factor-α and IL-8 via the inhibition of MAPKs phosphorylation in HMC-1 cells.
These results suggest that ID is a potential therapeutic agent for allergic inflammatory diseases, including dermatitis.
Atopic dermatitis (AD), also known as atopic eczema, is a common, chronic and allergic inflammatory skin disease . The worldwide prevalence rate of AD is nearly 10-20 % in children and 1–3 % in adults. Genetic and environmental factors are important causes in many AD patients . Immune system disorders cause AD, which is related to several types of cells (T lymphocytes, macrophages, mast cells, and keratinocytes), specifically T helper (Th) cell dysfunction and IgE production [3, 4].
Ixeris dentata Nakai (Compositae) has been used for the treatment of mithridatism, calculous, indigestion, pneumonia, hepatitis, and tumors in Korea, China, and Japan . It has been reported that Ixeris dentata has neuroprotective effects , anti-diabetic effects , protection effects against colitis and skin inflammation [8, 9], and anti-allergic effects [10, 11]. In this study, the effect of the Ixeris dentata water extract (ID) on allergic inflammatory reactions via MAPKs signaling was investigated in human keratinocytes and human mast cells and was also assessed in vivo.
Keratinocytes, which are the main type of epidermal cells, play a key role in the pathogenesis of AD . Epidermal keratinocytes release various inflammatory mediators, such as chemokines and adhesion molecules by tumor necrosis factor (TNF)-α and interferon (IFN)-γ stimulations [13, 14]; these factors are involved in the development of inflammatory skin diseases, including AD. Thymus and activation-regulated chemokine (TARC or CCL17) as well as macrophage-derived chemokine (MDC or CCL22), which are Th2 chemokines, mediate the migration of lymphocytes to inflammatory sites and aggravate AD . Additionally, the levels of TARC and MDC are elevated in serum and skin lesions of AD patients [16, 17].
Mast cells are hematopoietic cells that originate from progenitor cells in the bone marrow. They are considered as key effector cells in IgE-mediated immediate hypersensitivity and allergic disorders . In response to various stimuli, mast cells secrete a variety of bioactive substances, such as histamine and several proinflammatory cytokines, including interleukin (IL)-8 and TNF. These mediators contribute to inflammation through the recruitment and activation of immune cells . Mast cells are increased in a majority of AD patients and are believed to be involved in the pathogenesis of AD .
Nuclear factor-kappaB (NF-κB) plays a pivotal role in the regulation of immune and inflammatory responses through the expression of cytokine, chemokine, and adhesion molecules. When IκB proteins are phosphorylated and degraded after stimulation, NF-κB is translocated into the nucleus and initiates the transcription of genes that are crucial in the development of inflammatory diseases. Therefore, the activation of NF-κB is important in the progression of allergic inflammation [21–23].
Mitogen-activated protein kinases (MAPKs) signaling pathway controls a vast array of physiological processes. In multicellular organisms, there are three well-characterized subfamilies of MAPKs. These MAPKs include the extracellular signal-regulated kinases (ERKs); the c-jun N-terminal kinases (JNKs); and the p38 MAPKs . It has shown to be important in the proliferation, activation, degranulation, and migration of various immune cells. The activation of MAPKs is associated with the allergic inflammatory response via the translocation of NF-κB, which causes the production of proinflammatory cytokines and chemokines [25–27]. Synthetically, the inhibition of NF-κB and MAPKs activation has been suggested as an anti-inflammatory strategy in allergic inflammation.
In this study, we evaluated the effect of ID on DNFB-induced AD-like skin lesion and anaphylactic shock in mouse models. We also examined the inhibitory effects of ID and its major compound, caffeic acid, on the productions of TNF-α/IFN-γ-induced chemokines and adhesion molecules in the human keratinocyte HaCaT cell line. Moreover, the effects of ID and caffeic acid on phorbol 12-myristate 13-acetate (PMA)/calcium ionophore A23187 (A23287)-induced proinflammatory cytokines productions as well as its mechanisms were investigated in human mast cells (HMC-1).
Antibodies and reagents
2, 4-dinitrofluorobenzene (DNFB), compound 48/80, 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), PMA, and A23187 were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Avidin peroxidase (AP), fetal bovine serum (FBS), Roswell Park Memorial Institute (RPMI) 1640, and Iscove's Modified Dulbecco's Medium (IMDM) were purchased from Gibco BRL (Grand Island, NY, USA). Anti-human TNF-α/IL-6/IL-8, recombinant TNF-α/IL-6/IL-8, biotinylated TNF-α/IL-6/IL-8, anti-mouse IgE/IL-1β, recombinant IgE, IL-1β, biotinylated IgE, and IL-1β were purchased from BD Pharmingen (San Diego, CA, USA). Anti-phospho p38 antibody was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Anti-phospho ERK, JNK, IκBα, anti-p38, JNK, NF-κB, histone, and GAPDH antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-ERK, and α-tubulin antibodies were purchased from Bioworld Technology (Minneapolis, MN, USA).
BALB/c mice (5 weeks, male, 19–20 g) were purchased from Da-Mool science (Daejeon, Republic of Korea). The animals were housed in a laminar air-flow room maintained at a temperature of 22 ± 1 °C and a reactive humidity level of 55 ± 1 % throughout the study. All animal experimental processes were approved by the Wonkwang University Institutional Animal Care and Use Committee (Confirmation No. WKU14-34).
Preparation of ID
Ixeris dentata was obtained from the Wonkwang Institute of Biomedical Engineering Research and authenticated by Professor S. J. Park, College of Korean Medicine, Wonkwang University. A voucher specimen (No. 05-17-12) was deposited at the Herbarium of the College of Pharmacy, Wonkwang University. It was prepared by decocting a dried prescription of herbs with distilled water for 3 h. The extract was filtered, lyophilized, and kept at 4 °C. The samples were dissolved in distilled water and then filtered through a 0.22 μm syringe filter. The yield of the dried extract from the starting materials was about 7.8 %. A caffeic acid content analysis revealed a concentration of 4 ± 0.00 mg/g (0.4 ± 0.00 %) .
Experiments were performed according to a previously described method . The dorsal skin of BALB/c mice (n = 7) was shaved by depilatory equipment before the experiment. The mice were sensitized with 100 μl of 0.15 % DNFB in an acetone olive oil (3: 1) or a vehicle applied to the dorsal skin twice each week for six weeks. ID (1 mg/kg) was orally administrated six weeks during the experiment.
Dermatitis skins samples were excised from the mice 24 h after the final DNFB application and fixed with 10 % formaldehyde, embedded in paraffin wax, routinely processed and then sectioned into 4-μm-thick slices. The skin sections were then stained with hematoxylin and eosin and examined by light microscopy for the presence of edema and for inflammatory cell accumulation.
Enzyme-linked immunosorbent assay (ELISA)
96-well plates were coated with capture antibodies overnight at 4 °C. After washing with PBST, samples and cytokine standards were added and incubated at 37 °C for 2 h. The plates were washed and biotinylated antibodies were added. The samples were then left for 2 h. After washing, the plates were incubated with AP for 30 min in an incubator set to a temperature of 37 °C. Finally, TBS substrate solution was added and color development was measured by a microplate reader at 405 nm.
Preparation of total cell lysates and nuclear extracts and western blot analysis
Stimulated cells were rinsed with ice-cold PBS and lysed using lysis buffer (iNtRon Biotech, Seoul, Republic of Korea) for 1 h. Total cell lysates were centrifuged for 10 min at 4 °C, after which the supernatants were obtained. Nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Thermo Scientific, Rockford, USA). After bicinchoninic acid (BCA) protein quantification, the supernatant was mixed with a 2× sample buffer, boiled for 5 min, separated by 10 % SDS-polyacrylamide gel electrophoresis, and then transferred to nitrocellulose membranes. The membranes were blocked with 10 % skim milk for 1 h and 30 min and incubated for 3 h with primary antibodies. They were then incubated with secondary antibodies for 45 min. Protein bands were detected using an ECL solution.
The mice (n = 5) were administrated intraperitoneal injections of compound 48/80 (8 mg/kg). Control mice received a vehicle (PBS) and ID (0.01 - 1 g/kg) was orally administrated 1 h prior to the injection of compound 48/80. Mortality was monitored for 1 h after the induction of anaphylactic shock.
Human immortalized keratinocytes (HaCaT cells) in RPMI 1640 supplemented with 10 % FBS, 100 units/ml of penicillin, and 100 μg/ml of streptomycin were cultured in a humidified atmosphere of 5 % CO2/95 % air at 37 °C. The human mast cell line (HMC-1) were cultured in IMDM supplemented with 10 % FBS, 100 units/ml of penicillin, and 100 μg/ml of streptomycin in a humidified atmosphere of 5 % CO2/95 % air at 37 °C.
An MTT assay was performed to investigate the cell toxicity of ID and caffeic acid. MTT solution (500 μg/ml) was added, followed by incubation at 37 °C for 4 h. The crystallized formazan was dissolved in DMSO and the absorbance was measured at 540 nm by a microplate reader.
Reverse-transcriptase polymerase chain reaction (RT-PCR)
Sequences of the RT-PCR primers
The results are shown as a summary of the data from three experiments and are presented as the mean ± SD. A statistical evaluation of the results was performed by the Student’s t-test. For all experiments, p < 0.05 was considered to be significant.
Effect of ID on DNFB-induced dermatitis and serum IgE and IL-1β levels
Effect of ID on the phosphorylation of MAPKs and transcription factors in DNFB-induced skin lesions
Effect of ID on compound 48/80-induced anaphylactic shock
Effect of ID on the compound 48/80-induced systemic anaphylactic reaction
Compound 48/80 (8 mg/kg)b
Effects of ID and caffeic acid on the expression of chemokines in HaCaT cells
Effects of ID on the production of proinflammatory cytokines and the activation of MAPKs in HMC-1 cells
Effects of caffeic acid on the production of proinflammatory cytokines and the activation of MAPKs in HMC-1 cells
AD is a chronic inflammatory skin disease associated with cutaneous hyperreactivity to environmental triggers and skin inflammatory responses driven by cytokines expression. Furthermore, the incidence of AD has continued to increase over the past several decades . Common treatments for AD are steroid therapy and immunosuppressive drugs, but these show side-effects, especially with continuous application . Therefore, researchers have attempted to find a new drug in complementary and alternative medicines, such as herbal medicines [31, 32]. In this study, we demonstrated the regulatory effect of ID on allergic reactions in vivo and in vitro.
Haptens such as DNFB are used to induce a model of murine-contact hypersensitivity (MCH). It has been reported that MCH can generate AD-like skin lesions and immune responses with Th1-and/or Th2-type inflammation under certain conditions . Dermatitis is characterized as a potent form of skin inflammation associated with an elevated level of IgE and the activation of IL-1β [34–36]. In this study, we mainly focused on the regulation of ID on proinflammatory cytokines but not Th2 cytokines, since it has been reported that the inhibitory effect of ID on DSS-induced colitis is due to the reduction of proinflammatory cytokines including TNF-α and IL-6 in previous study . Therefore, we repeated the application of DNFB to induce AD-like lesions in BALB/c mice and investigated an effect of ID treatment. ID significantly reduced DNFB-induced dermatitis and decreased the serum levels of IgE and the IL-1β via the inhibition of p38, ERK, and JNK phosphorylation as well as the activation of NF-κB in AD-like skin lesions (Fig. 1 and 2). Compound 48/80, one of the most potent secretagogues, increases the permeability of the lipid bilayer membrane by causing a perturbation in the membrane upon mast cell degranulation . ID administration also inhibited compound 48/80-induced anaphylactic shock in dose-dependent manner (Table 2). These results indicate that ID has a potent effect on anti-allergic responses in mice model.
HaCaT cells, a spontaneously transformed human keratinocyte cell line, are commonly used in pharmacological studies of skin diseases such as dermatitis, as it produces proinflammatory cytokines and chemokines upon various types of stimulation. HaCaT cells develop skin-associated lymphoid tissue by increasing the levels of surface antigens and interacting with other immunocytes . TARC and MDC, typical Th2 chemokines, are both induced in HaCaT cells upon stimulation with IFN-γ and TNF-α . As the chemokine, IL-8 plays a role in the activation of inflammatory effector cells such as neutrophils, T-lymphocytes, and eosinophils . In this study, ID inhibited the mRNA expression of chemokines (IL-8, TARC, and MDC), and the adhesion molecule (ICAM-1), and MMP-9. Caffeic acid also reduced the expressions of IL-8 and TARC in TNF-α/IFN-γ-stimulated HaCaT cells (Fig. 3).
Mast cells play an important role in both adaptive and innate immunity and show increases in immunological skin diseases, including dermatitis . The HMC-1 cell line was established from leukemia patients; it expresses characteristic markers for mast cells . In response to different types of stimulation, mast cells release an array of cytokines, especially TNF-α, IL-6, and IL-8, with the potential to cause inflammation . Therefore, the inhibition of cytokine secretion can be a useful therapeutic strategy for allergic inflammatory diseases such as AD. In this study, we demonstrated that ID and caffeic acid decreased the production of TNF-α and IL-8 in PMA + A23187-stimulated HMC-1 cells (Fig. 4 and 5). The expressions of proinflammatory cytokines such as TNF-α, IL-6, and IL-8 are associated with the activation of MAPKs and transcription factor NF-κB [25, 26]. To elucidate the mechanisms of the ID-mediated inhibition of proinflammatory cytokine production, we examined the regulatory effect of ID on the intracellular signaling molecules involved in the PMA + A23187-induced signaling pathways. ID decreases the nuclear translocation of NF-κB via the p38 and ERK, whereas caffeic acid regulates the phosphorylation of p38 but not ERK or JNK (Fig. 4 and 5). These results demonstrate that ID and caffeic acid suppress the production of proinflammatory cytokines through the phosphorylation of MAPKs and the activation of the NF-κB pathway. In contrast, we were unable to find the inhibitory effect of ID and caffeic acid on IL-6 production. Other studies demonstrated that IL-6 production is regulated by JNK activation in renal epithelial cells and PMA-stimulated Jurkat T cells [43, 44]. Since the drugs might not affect JNK activation, consequently both drugs did not decrease the IL-6 production.
In a previous study, we found that ID contained approximately 4 mg/g of caffeic acid (3,4-dihydroxy cinamic acid) . Approximately 20 types of sesquiterpene and other compounds have been isolated from ID. It has been reported that its main compounds are luteolin, luteolin 7-O-glucuronide, caffeic acid, chlorogenic acid, and guaiane sesquiterpene lactones [45, 46]. Among these main compounds, inhibitory effects of luteolin, chlorogenic acid, and tectroside on allergic inflammation had already been reported [9,47–49]. Thus, we focused on ID and caffeic acid and demonstrated both drugs’ anti-allergic inflammatory effect on HaCaT and HMC-1 cells. Caffeic acid was effective for reducing inflammatory responses with regard to TPA-induced ear thickness, and TPA/calcium ionophore or TNF-α-stimulated HaCaT cells [50, 51]. Therefore, caffeic acid may be partly responsible for the anti-allergic effect of ID. Indeed, we showed in present study that caffeic acid reduced the expressions of IL-8 and TARC as well as p38/NF-κB pathway in TNF-α/IFN-γ-stimulated HaCaT cells and HMC-1 cells.
In this study, ID decreased the production of proinflammatory cytokines including TNF-α and IL-8 in mast cells and inhibited TNF-α/IFN-γ-induced expression of chemokines such as IL-8, TARC and MDC in HaCaT cells. We showed that ID also reduced the expression of MMP-9, which is induced by histamine in keratinocyte . Yi et al.  reported that ID inhibited the histamine release in mast cells. Therefore we suggest that reduced MMP-9 expression in keratinocytes by ID may be due to inhibition of ID on histamine release. These responses might also be occurred via blockage of the p38 and ERK/NF-κB pathway in mast cells and keratinocytes by ID treatment. In addition, MAPKs/NF-κB activation was inhibited by ID administration in AD-like skin lesion mice model. Consequently, ID water extract can improve the allergic inflammatory diseases through inhibition of proinflammatory cytokines, chemokines, and MMP-9 by regulation of MAPKs/NF-κB pathway in mast cells and keratinocytes.
Our data suggest that ID can be used in the treatment of allergic skin diseases, including AD. ID showed anti-inflammatory and anti-allergic activities by suppressing skin dermatitis in DNFB-sensitized mice and compound 48/80-induced systemic anaphylaxis through the inhibition of serum IgE and IL-1β release. In addition, ID inhibited the TNF-α/IFN-γ-induced expression of chemokines (IL-8, TARC, and MDC), ICAM-1, and MMP-9 in keratinocytes. Moreover, ID reduced proinflammatory cytokines (TNF-α and IL-8) via the blockage of p38/ERK phosphorylation and NF-κB activation in mast cells. These results lend insight into the pharmacological actions of ID as a potential therapy for allergic inflammatory diseases such as dermatitis.
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2012M2B2B1055244, No. 2011–0030130, and No. 2011–0006220).
- Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151–60.View ArticlePubMedGoogle Scholar
- Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004;113:651–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Bonness S, Bieber T. Molecular basis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007;7:382–6.View ArticlePubMedGoogle Scholar
- Novak N. New insights into the mechanism and management of allergic diseases: atopic dermatitis. Allergy. 2009;64:265–75.View ArticlePubMedGoogle Scholar
- Ahn EM, Bang MH, Song MC, Park MH, Kim HY, Kwon BM, et al. Cytotoxic and ACAT-inhibitory sesquiterpene lactones from the root of Ixeris dentata forma albiflora. Arch Pharm Res. 2006;29:937–41.View ArticlePubMedGoogle Scholar
- Oh SH, Sung TH, Kim MR. Ixeris dentata extract maintains glutathione concentrations in mouse brain tissue under oxidative stress induced by kainic acid. J Med Food. 2003;6:353–8.View ArticlePubMedGoogle Scholar
- Lee HY, Lee GH, Kim HK, Kim SH, Kp P, Chae HJ, et al. Ixeris dentata-induced regulation of amylase synthesis and secretion in glucose-treated human salivary gland cells. Food Chem Toxicol. 2013;62:739–49.View ArticlePubMedGoogle Scholar
- Kim DS, Ko JH, Jeon YD, Han YH, Kim HJ, Poudel A, et al. Ixeris dentata NAKAI Reduces Clinical Score and HIF-1 Expression in Experimental Colitis in Mice. Evid Based Complement Alternat Med. 2013;2013:671281.PubMedPubMed CentralGoogle Scholar
- Kim SB, Kang OH, Joung DK, Mun SH, Seo YS, Cha MR, et al. Anti-inflammatory effects of tectroside on UVB-induced HaCaT cells. Int J Mol Med. 2013;31:1471–6.PubMedGoogle Scholar
- Yi JM, Hong SH, Lee HJ, Won JH, Kim JM, Jeong DM, et al. Ixeris dentata green sap inhibits both compound 48/80-induced aanaphylaxis-like response and IgE-mediated anaphylactic response in murine model. Biol Pharm Bull. 2002;25:5–9.View ArticlePubMedGoogle Scholar
- Park EK, Sung JH, Trinh HT, Bae EA, Yun HK, Hong SS, et al. Lactic acid bacterial fermentation increases the antiallergic effects of Ixeris dentata. J Microbiol Biotechnol. 2008;18:308–13.PubMedGoogle Scholar
- Albanesi C. Keratinocytes in allergic skin diseases. Curr Opin Allergy Clin Immunol. 2010;10:452–6.View ArticlePubMedGoogle Scholar
- Pastore S, Lulli D, Potapovich AI, Fidanza P, Kostyuk VA, Dellambra E, et al. Differential modulation of stress-inflammation responses by plant polyphenols in cultured normal human keratinocytes and immortalized HaCaT cells. J Dermatol Sci. 2011;63:104–14.PubMedGoogle Scholar
- Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol. 2000;115:81–7.View ArticlePubMedGoogle Scholar
- Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci. 2006;43:75–84.View ArticlePubMedGoogle Scholar
- Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol. 2004;113:334–40.View ArticlePubMedGoogle Scholar
- Leung TF, Ma KC, Hon KL, Lam CW, Wan H, Li CY, et al. Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children. Pediatr Allergy Immunol. 2003;14:296–301.View ArticlePubMedGoogle Scholar
- Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749–86.View ArticlePubMedGoogle Scholar
- Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol. 2010;40:1843–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Kawakami T, Ando T, Kimura M, Wilson BS, Kawakami Y. Mast cells in atopic dermatitis. Curr Opin Immunol. 2009;21:666–78.View ArticlePubMedPubMed CentralGoogle Scholar
- Finco TS, Baldwin AS. Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Immunity. 1995;3:263–72.View ArticlePubMedGoogle Scholar
- Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–71.View ArticlePubMedGoogle Scholar
- Barnes PJ. Pathophysiology of allergic inflammation. Immunol Rev. 2011;242:31–50.View ArticlePubMedGoogle Scholar
- Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911–2.View ArticlePubMedGoogle Scholar
- Hommes DW, Peppelenbosch MP, van Deventer SJ. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut. 2003;52:144–51.View ArticlePubMedPubMed CentralGoogle Scholar
- May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today. 1998;19:80–8.View ArticlePubMedGoogle Scholar
- Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13:679–92.View ArticlePubMedGoogle Scholar
- Kim SJ, Kee JY, Choi IY, Kim MC, Kim DS, Jeon YD, et al. Insamhodo-tang, a traditional Korean medicine, regulates mast cell-mediated allergic inflammation in vivo and in vitro. J Ethnopharmacol. 2011;134:339–47.View ArticlePubMedGoogle Scholar
- Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol. 2003;21:579–628.View ArticlePubMedGoogle Scholar
- Cohen DE, Heidary N. Treatment of irritant and allergic contact dermatitis. Dermatol Ther. 2004;17:334–40.View ArticlePubMedGoogle Scholar
- Tan HY, Zhang AL, Chen D, Xue CC, Lenon GB. Chinese herbal medicine for atopic dermatitis: a systematic review. J Am Acad Dermatol. 2013;69:295–304.View ArticlePubMedGoogle Scholar
- Yamashita H, Tanaka H, Inagaki N. Treatment of the chronic itch of atopic dermatitis using standard drugs and kampo medicines. Biol Pharm Bull. 2013;36:1253–7.View ArticlePubMedGoogle Scholar
- Honda T, Egawa G, Grabbe S, Kabashima K. Update of immune events in the murine contact hypersensitivity model: toward the understanding of allergic contact dermatitis. J Invest Dermatol. 2013;133:303–15.View ArticlePubMedGoogle Scholar
- Allam JP, Novak N. The pathophysiology of atopic eczema. Clin Exp Dermatol. 2006;31:89–93.View ArticlePubMedGoogle Scholar
- Liu FT, Goodarzi H, Chen HY. IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol. 2011;41:298–310.View ArticlePubMedGoogle Scholar
- Watanabe H, Gaide O, Pétrilli V, Martinon F, Contassot E, Roques S, et al. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol. 2007;127:1956–63.View ArticlePubMedGoogle Scholar
- Tasaka K, Mio M, Okamoto M. Intracellular calcium release induced by histamine releasers and its inhibition by some antiallergic drugs. Ann Allergy. 1986;56:464–9.PubMedGoogle Scholar
- Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol. 1988;106:761–71.View ArticlePubMedGoogle Scholar
- Horikawa T, Nakayama T, Hikita I, Yamada H, Fujisawa R, Bito T, et al. IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int Immunol. 2002;14:767–73.View ArticlePubMedGoogle Scholar
- Sebastiani S, Albanesi C, De PO, Puddu P, Cavani A, Girolomoni G. The role of chemokines in allergic contact dermatitis. Arch Dermatol Res. 2002;293:552–9.View ArticlePubMedGoogle Scholar
- Navi D, Saegusa J, Liu FT. Mast cells and immunological skin diseases. Clin Rev Allergy Immunol. 2007;33:144–55.View ArticlePubMedGoogle Scholar
- Hamann K, Grabbe J, Welker P, Haas N, Algermissen B, Czarnetzki BM. Phenotypic evaluation of cultured human mast and basophilic cells and of normal human skin mast cells. Arch Dermatol Res. 1994;286:380–5.View ArticlePubMedGoogle Scholar
- de Haij S, Bakker AC, van der Geest RN, Haegeman G, Vanden Berghe W, Aarbiou J, et al. NF-kappaB mediated IL-6 production by renal epithelial cells is regulated by c-jun NH2-terminal kinase. J Am Soc Nephrol. 2005;16:1603–11.View ArticlePubMedGoogle Scholar
- Khalaf H, Jass J, Olsson PE. Differential cytokine regulation by NF-kappaB and AP-1 in Jurkat T-cells. BMC Immunol. 2010;11:26.View ArticlePubMedPubMed CentralGoogle Scholar
- Cha MR, Choi YH, Choi CW, Yoo DS, Kim YS, Choi SU, et al. New guaiane sesquiterpene lactones from Ixeris dentata. Planta Med. 2011;77:380–2.View ArticlePubMedGoogle Scholar
- Karki S, Park HJ, Nugroho A, Kim EJ, Jung HA, Choi JS. Quantification of major compounds from Ixeris dentata, Ixeris dentata Var. albiflora, and Ixeris sonchifolia and their comparative anti-inflammatory activity in lipopolysaccharide-stimulated RAW 264.7 cells. J Med Food. 2015;18:83–94.View ArticlePubMedGoogle Scholar
- Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P, et al. Luteolin inhibits mast cell-mediated allergic inflammation. J Biol Regul Homeost Agents. 2013;27:955–9.PubMedGoogle Scholar
- Kwon OS, Choi JS, Islam MN, Kim YS, Kim HP. Inhibition of 5-lipoxygenase and skin inflammation by the aerial parts of Artemisia capillaris and its constituents. Arch Pharm Res. 2011;34:1561–9.View ArticlePubMedGoogle Scholar
- Trinh HT, Bae EA, Hyun YJ, Jang YA, Yun HK, Hong SS, et al. Anti-allergic effects of fermented Ixeris sonchifolia and its constituent in mice. J Microbiol Biotechnol. 2010;20:217–23.PubMedGoogle Scholar
- Zhang M, Zhou J, Wang L, Li B, Guo J, Guan X, et al. Caffeic acid reduces cutaneous tumor necrosis factor alpha (TNF-α), IL-6 and IL-1β levels and ameliorates skin edema in acute and chronic model of cutaneous inflammation in mice. Biol Pharm Bull. 2014;37:347–54.View ArticlePubMedGoogle Scholar
- Hossen MA, Inoue T, Shinmei Y, Minami K, Fujii Y, Kamei C. Caffeic acid inhibits compound 48/80-induced allergic symptoms in mice. Biol Pharm Bull. 2006;29:64–6.View ArticlePubMedGoogle Scholar
- Harvima IT. Induction of matrix metalloproteinase-9 in keratinocytes by histamine. J Invest Dermatol. 2008;128:2748–50.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.